Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Posted on by sciencefather

Dr. Xufen Yu | Medicinal Chemistry | Best Researcher Award

Dr. Xufen Yu | Medicinal Chemistry | Associate Professor at Fudan University, China

Dr. Xufen Yu is an Associate Professor in the Department of Medicinal Chemistry at Fudan University’s School of Pharmacy. She specializes in drug discovery, chemical biology, and targeted protein degradation, particularly in cancer therapeutics. Before joining Fudan University, she was an Instructor and Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, where she contributed significantly to pharmacological sciences. Dr. Yu has also held postdoctoral positions at Purdue University and the University of Hawaii at Hilo. She holds a Ph.D. from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry. Her research has led to numerous high-impact publications in journals such as Journal of Medicinal Chemistry, Oncogene, and Nature Cancer. With extensive expertise in PROTAC-based therapeutics and epigenetic regulation, Dr. Yu continues to make significant contributions to the field of medicinal chemistry and targeted cancer therapy.

Professional Profile : 

Google Scholar

Orcid

Scopus  

Summary of Suitability for Award:

Dr. Xufen Yu is an exceptionally accomplished researcher in medicinal chemistry, with significant contributions to drug discovery, targeted protein degradation, and epigenetics. Her extensive academic background, including a Ph.D. from the Chinese Academy of Sciences and postdoctoral research at prestigious institutions such as Purdue University and the Icahn School of Medicine at Mount Sinai, demonstrates her expertise in chemical biology and small-molecule therapeutics. She has consistently advanced the field through high-impact publications, innovative research, and groundbreaking discoveries in PROTACs and DUBTACs, which have transformed targeted cancer therapy.  Given her outstanding achievements, innovative research, and contributions to medicinal chemistry, Dr. Xufen Yu is highly suitable for the “Best Researcher Award”. Her pioneering work in targeted protein degradation, combined with her international recognition and research excellence, makes her a strong candidate. Her research has not only advanced scientific knowledge but also holds significant promise for therapeutic applications, reinforcing her eligibility for this distinguished honor.

🎓Education:

Dr. Xufen Yu earned her Ph.D. in Organic Chemistry from the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, in 2011. Her doctoral research focused on synthetic organic chemistry and drug discovery. Prior to that, she completed her undergraduate studies at Anhui University, Hefei, China, earning a Bachelor’s degree in Chemistry in 2006. With a strong academic foundation, Dr. Yu developed expertise in medicinal chemistry, chemical biology, and targeted protein degradation. Her educational journey equipped her with extensive knowledge of molecular design, synthetic methodologies, and structure-activity relationship studies, laying the groundwork for her future contributions to pharmacological sciences. Her rigorous training in organic synthesis and chemical biology has driven her impactful research in developing novel therapeutics, particularly in targeted protein degradation and epigenetic regulation.

🏢Work Experience:

Dr. Xufen Yu has had a distinguished career in academia and research, with extensive postdoctoral and faculty experience. She is currently an Associate Professor in the Department of Medicinal Chemistry at Fudan University, Shanghai, China. Before joining Fudan, she was an Instructor in the Department of Pharmacological Science at the Icahn School of Medicine at Mount Sinai, New York (2021–2022), following a postdoctoral fellowship at the same institution from 2017 to 2020. She also worked as a postdoctoral fellow in Chemistry at Purdue University (2013–2014) and in Pharmaceutical Science at the University of Hawaii at Hilo (2011–2013). Through these roles, she has contributed significantly to medicinal chemistry, focusing on drug discovery, targeted protein degradation, and cancer therapeutics. Her work across multiple prestigious institutions reflects her expertise in interdisciplinary research, integrating chemistry and pharmacology to develop novel small-molecule therapeutics.

🏅Awards: 

Dr. Xufen Yu has been recognized for her outstanding contributions to medicinal chemistry and drug discovery. She has received multiple awards and research grants for her pioneering work in targeted protein degradation and epigenetics. Her innovative research has been acknowledged with prestigious fellowships and funding from institutions such as the National Institutes of Health (NIH) and the Chinese Academy of Sciences. Additionally, she has been honored for her significant publications in high-impact journals, receiving accolades for breakthrough studies on PROTACs and epigenetic regulators in cancer therapy. Her commitment to scientific excellence has led to invitations as a speaker at international conferences, where she has shared her expertise in medicinal chemistry. Dr. Yu’s contributions have been instrumental in advancing chemical biology and therapeutic discovery, making her a well-respected figure in her field.

🔬Research Focus:

Dr. Xufen Yu’s research focuses on the development of novel therapeutic strategies targeting disease-related proteins, particularly in cancer and metabolic disorders. Her expertise lies in targeted protein degradation, including the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) and DUBTACs (Deubiquitinase Targeting Chimeras). She has explored epigenetic regulation in cancer therapy, investigating how small molecules can modulate oncogenic transcription factors and chromatin regulators. Her work also includes studying the role of ubiquitin-proteasome and autophagy systems in disease mechanisms, aiming to develop highly selective small-molecule therapeutics. Through interdisciplinary approaches combining medicinal chemistry, chemical biology, and pharmacology, she has contributed to advancing targeted cancer treatments. Dr. Yu’s research has led to the discovery of several potent and selective degraders for oncogenic proteins such as EZH2, WDR5, and USP7, paving the way for new treatment modalities in oncology.

Publication Top Notes:

Macrocyclic drugs and synthetic methodologies toward macrocycles
Authors: X Yu, D Sun
Citations: 276
Year: 2013

Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism
Authors: AJ Bott, J Shen, C Tonelli, L Zhan, N Sivaram, YP Jiang, X Yu, V Bhatt, …
Citations: 155
Year: 2019

Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders
Authors: M Cheng, X Yu, K Lu, L Xie, L Wang, F Meng, X Han, X Chen, J Liu, …
Citations: 151
Year: 2020

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Authors: J Wang, X Yu, W Gong, X Liu, KS Park, A Ma, YH Tsai, Y Shen, T Onikubo, …
Citations: 134
Year: 2022

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Authors: X Yu, D Li, J Kottur, Y Shen, HS Kim, KS Park, YH Tsai, W Gong, J Wang, …
Citations: 103
Year: 2021

Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders
Authors: Y Shen, G Gao, X Yu, H Kim, L Wang, L Xie, M Schwarz, X Chen, …
Citations: 84
Year: 2020

Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery
Authors: AM Chiarella, KV Butler, BE Gryder, D Lu, TA Wang, X Yu, S Pomella, …
Citations: 77
Year: 2020

Cationic Palladium Complex Catalyzed Diastereo-and Enantioselective Tandem Annulation of 2-Formylarylboronic Acids with Allenoates
Authors: X Yu, X Lu
Citations: 57
Year: 2009

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B
Authors: J Xu, X Yu, TC Martin, A Bansal, K Cheung, A Lubin, E Stratikopoulos, …
Citations: 51
Year: 2021

Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders
Authors: X Yu, J Xu, L Xie, L Wang, Y Shen, KM Cahuzac, X Chen, J Liu …
Citations: 42
Year: 2021

Prof. Hendrik G Kruge | Pharmaceutical Chemistry | Best Researcher Award

Posted on by sciencefather

Prof. Hendrik G Kruge | Pharmaceutical Chemistry | Best Researcher Award

Prof. Hendrik G Kruge , University of KwaZulu-Natal , South Africa

Prof. Hendrik Gerhardus Kruger is a distinguished Research Professor in Health Sciences at the University of KwaZulu-Natal, South Africa. With a specialization in organic chemistry, molecular modeling, and drug design, he has significantly impacted the scientific community. Holding a PhD in Chemistry from Potchefstroom University, he has published over 400 research papers and has mentored more than 100 postgraduate students and 30 postdoctoral fellows. Kruger is recognized for his contributions to curriculum development and his service to the scientific community. As a Fellow of the South African Chemical Institute, he has played a vital role in advancing research initiatives in the region. His innovative approach to rational drug design has positioned him among the leading scientists on the African continent, dedicated to addressing critical health challenges through cutting-edge research.

Professional Profile:

Google Scholar

Orcid

Scopus

Summary of Suitability for Award:

Prof. Hendrik Gerhardus Kruger is an exemplary candidate for the “Best Researcher Awards” due to his extensive contributions to the fields of chemistry and health sciences. His designation as a top researcher at the University of KwaZulu-Natal is a reflection of his innovative approach to drug design and molecular modeling, which has had a profound impact on the scientific community. Prof. Kruger’s work on metallo-beta-lactamase inhibitors, particularly the successful patent that is currently under consideration for clinical trials, demonstrates his ability to translate research into tangible health solutions.

🎓Education:

Prof. Hendrik Gerhardus Kruger obtained his PhD in Chemistry from Potchefstroom University, South Africa. His academic journey laid a strong foundation in organic chemistry, enabling him to specialize in molecular modeling and drug design. Throughout his educational career, he has continually sought to expand his knowledge and expertise, attending various workshops and conferences both nationally and internationally. His commitment to education extends beyond his own studies, as he has actively participated in mentoring students and developing curricula at the University of KwaZulu-Natal. His academic rigor and dedication to advancing chemical sciences have established him as a respected educator and researcher, contributing to the academic landscape in South Africa and beyond. Prof. Kruger’s comprehensive understanding of chemistry and its applications has driven his research endeavors and shaped his contributions to health sciences and drug development.

🏢Work Experience:

Prof. Hendrik Gerhardus Kruger boasts extensive experience in the field of chemistry, particularly in health sciences and drug design. As a Research Professor at the University of KwaZulu-Natal, he has led various research initiatives that emphasize rational drug design and biochemical analysis. Over the years, he has published more than 400 scientific papers and supervised over 100 postgraduate students and 30 postdoctoral fellows, reflecting his commitment to fostering the next generation of scientists. His leadership roles include serving on editorial boards for several reputable journals, including the South African Journal of Chemistry, where he has contributed to the advancement of organic chemistry. Kruger’s experience is further highlighted by his active involvement in industry collaborations, focusing on the development of innovative therapeutic solutions. His holistic approach to research, combining academic rigor with practical applications, has solidified his reputation as a leading figure in his field.

🏅Awards:

Prof. Hendrik Gerhardus Kruger has received numerous accolades for his outstanding contributions to the field of chemistry and health sciences. He is recognized as a top researcher at the University of KwaZulu-Natal, where his innovative work in drug design and molecular modeling has garnered significant attention. As a Fellow of the South African Chemical Institute (SACI), he has been acknowledged for his leadership and influence within the chemical community. His patent for metallo-beta-lactamase inhibitors, currently considered for clinical trials, is a testament to his impactful research. Kruger’s work has also earned him editorial appointments, where he has shaped the direction of scientific publishing. His recognition extends beyond academia, as he is often invited to speak at international conferences, further highlighting his expertise and commitment to advancing scientific knowledge. These honors reflect his dedication to excellence and his role in elevating the standards of chemical research.

🔬Research Focus:

Prof. Hendrik Gerhardus Kruger’s research focus centers on rational drug design, organic chemistry, and molecular modeling, with a commitment to addressing critical health challenges. His innovative work includes elucidating the mechanism of action of new metallo-beta-lactamase (MBL) inhibitors using advanced computational techniques such as hybrid quantum chemical methods and Umbrella sampling. Kruger is also expanding drug design efforts for second-generation MBL inhibitors and exploring new HIV integrase inhibitors. His research involves RNA analysis of pathogens to identify potential drug targets, aiming to enhance treatment strategies for diseases like tuberculosis (TB). By analyzing cellular processes at different treatment stages, his team seeks to shorten treatment times and improve patient outcomes. His multifaceted approach to drug development, combining fundamental research with practical applications, positions him at the forefront of chemical sciences and emphasizes his dedication to innovative therapeutic solutions.

Publication Top Notes:

  • Title: Green solid-phase peptide synthesis 2. 2-Methyltetrahydrofuran and ethyl acetate for solid-phase peptide synthesis under green conditions
    Citations: 7580
  • Title: Bis-and trisindolylmethanes (BIMs and TIMs)
    Citations: 643
  • Title: Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review
    Citations: 420
  • Title: The role of nanotechnology in the treatment of viral infections
    Citations: 388
  • Title: Therapeutic peptides